Deegan R, Wood A J
Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN.
Clin Pharmacol Ther. 1994 Aug;56(2):223-8. doi: 10.1038/clpt.1994.127.
Esmolol is an ultra-short-acting beta-blocker that is widely used to lower blood pressure in acute settings intraoperatively and in patients with hypertension. Other beta-blockers have not been used in this way because of the belief that beta-blockers do not acutely lower blood pressure. The purpose of this study was to determine if esmolol has a hypotensive effect that is greater than other beta-blockers at similar degrees of beta-blockade. Esmolol, metoprolol, and propranolol were administered intravenously at three doses chosen to produce comparable degrees of beta-blockade. In spite of achieving comparable beta-blockade, esmolol produced a greater reduction in blood pressure than the other beta-blockers, implying that the hypotensive effect of esmolol cannot be accounted for simply by beta-blockade. There was no evidence to support a direct vasodilatory action of esmolol, and esmolol did not lower plasma norepinephrine concentrations.
艾司洛尔是一种超短效β受体阻滞剂，广泛用于术中急性情况下及高血压患者的降压治疗。由于人们认为β受体阻滞剂不能急性降低血压，所以其他β受体阻滞剂未被如此使用。本研究的目的是确定在相似程度的β受体阻滞情况下，艾司洛尔的降压作用是否大于其他β受体阻滞剂。静脉给予艾司洛尔、美托洛尔和普萘洛尔三种剂量，这些剂量旨在产生相当程度的β受体阻滞。尽管实现了相当程度的β受体阻滞，但艾司洛尔比其他β受体阻滞剂使血压降低得更多，这意味着艾司洛尔的降压作用不能简单地用β受体阻滞来解释。没有证据支持艾司洛尔有直接血管舒张作用，且艾司洛尔未降低血浆去甲肾上腺素浓度。
